Table 1.
Variable | Male, N = 108 (n%) |
Female, N = 159 (n%) |
Total, N = 267 (n%) |
p-value (Male vs Female) |
---|---|---|---|---|
Age, year, Median (Range) | 45 (25–60) | 35 (21–65) | 38 (21–65) | 0.01 |
Age <40 years | 51 (47.2 %) | 93 (58.5 %) | 144 (53.9 %) | 0.21 |
Age 40–50 years | 21 (19.4 %) | 27 (17 %) | 48 (18 %) | |
Age >50 years | 36 (33.3 %) | 39 (24.5) | 75 (28.1 %) | |
BMI, kg/m2, Median (Range) | 25 (15–49) | 25 (15–41) | 25 (15–49) | 0.823 |
Low, BMI <18.5 | 5 (4.6 %) | 16 (10.1 %) | 21 (7.9 %) | 0.001 |
Ideal, BMI 18.5–22.9 | 13 (12 %) | 45 (28.3 %) | 58 (21.7 %) | |
Overweight, BMI 23.0–27.5 | 50 (46.3 %) | 62 (39 %) | 112 (41.9 %) | |
Obese, BMI >27.5 | 40 (37.0 %) | 36 (22.6 %) | 76 (28.5 %) | |
WHR, Median (Range) | 0.92 (0.68–1.21) | 0.91 (0.46–1.08) | 0.92 (0.46–1.21) | <0.001 |
Low WHR (<0.95, M; <0.80, F) | 61 (56.5 %) | 22 (13.8 %) | 83 (31.1 %) | 0.161 |
Normal WHR (0.96–1.0, M; 0.81–0.85, F) | 14 (13 %) | 29 (18.2 %) | 43 (16.1 %) | |
High (WHR >1.0, M; >0.85, F | 33 (30.6 %) | 108 (67.9 %) | 141 (52.8 %) | |
Days after Dose 1 Median (Range) |
360 (63–420) | 270 (58–420) | 360 (180–401) | 0.025 |
Days after Dose 2 Median (Range) |
270 (58–395) | 210 (13–395) | 300 (120–395) | 0.05 |
Vaccine Dose 3 Status | 38 (33.9 %) | 49 (28,5 %) | 90 (31.7 %) | 0.51 |
Days after Dose 3 Median (Range) |
49 (2–89) | 60 (2–150) | 52.5 (1–115) | 0.02 |
RT-PCR positivity | 97 (89.8 %) | 129 (81.1 %) | 226 (84.6 %) | 0.76 |
Need for Hospitalization | 27 (25 %) | 32 (20.1 %) | 59 (22.1 %) | 0.37 |
Need for supplementary oxygen | 6 (5.6 %) | 11 (6.9 %) | 17 (6.4 %) | 0.80 |
Comorbidity | 34 (31.5 %) | 59 (37.1 %) | 93 (34.8 %) | 0.36 |
Data were expressed as number (percentage) [n (%)] or median (range) as appropriate. Chi-square and Mann-Whitney tests were used to find out the association between categorical and continuous variables, respectively. P < 0.05 was considered as significant. BMI, Body Mass Index; WHR, Waist-Hip Ratio.